Business
AXIM Biotechnologies (OTCQB: AXIM) Takes on Opioid Epidemic with New Patent -- SECFilings.com
AXIM Biotechnologies (OTCQB: AXIM) Takes on Opioid Epidemic with New Patent -- SECFilings.com.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\n \n \n AXIM Biotechnologies (OTCQB: AXIM) Takes on Opioid Epidemic with New Patent -- SECFilings.com\n \n \nAXIM Biotechnologies (OTCQB: AXIM) Takes on Opioid Epidemic with New Patent -- SECFilings.com\n\nAXIM is a major investment of Medical Marijuana, Inc. (OTC PINK: MJNA), the first publicly traded cannabis company\n\n \n REDONDO BEACH, CA--(Marketwired - Jun 27, 2017) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering AXIM® Biotechnologies Inc. (OTCQB: AXIM) and its recent patent on cannabinoid and opioid combinations in chewing gum. Medical Marijuana Inc. (OTC PINK: MJNA), the first publicly traded cannabis company, holds about 22.7 million shares of AXIM Biotech stock.\n More than 12.5 million people misuse prescription opioids, according to the U.S. Department of Health and Human Services, while two million people have been formally diagnosed with an addiction. These addictions cause $78.5 billion in economic damages each year and lead to more than 33,000 deaths from overdose each year. Despite these issues, physicians have few alternatives for prescribing opioids for pain management.\n New Patent Addition\n AXIM Biotechnologies recently announced a patent on chewing gum with a controlled release of cannabinoids and opioid agonists and/or antagonists for addiction and/or dependence treatment. In addition, the same chewing gum formulation may be used for the treatment of chronic pain as an alternative to opioid-only treatment options, which could represent an enormous end market for future product lines.\n \"Opioid addiction is a serious global problem that affects the health, social, and economic welfare of all societies,\" said AXIM Biotech CEO Dr. George E. Anastassov, MD, DDS, MBA. \"Opioid addiction therapy depends on a variety of techniques. One of them is the replacement therapy, where an opioid is replaced with another less potent and less addictive opioid that curbs the cravings and reduces withdrawal symptoms.\"\n There is evidence that cannabinoids -- and cannabidiol (CBD) in particular -- may decrease cravings for narcotics. The company aims to provide these cannabinoids in microencapsulated form, which may improve its chewing gum's taste, prevent binding with the gum's base, control rele...